19 citations
,
April 2014 in “Hormones” Hormones and genetics play key roles in male and female baldness, which can affect mental health and may be linked to other health issues.
18 citations
,
October 2018 in “Journal of The American Academy of Dermatology” This review indicates that many former FDA category D and X systemic dermatologic medications may negatively impact male fertility, with further research needed to assess potential teratogenic effects.
17 citations
,
August 2015 in “Expert Opinion on Pharmacotherapy” This article discusses the social and psychological impact of hair disorders and the challenges in their treatment, but reports no new clinical results.
16 citations
,
May 2019 in “International Journal of Women's Dermatology” This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.
15 citations
,
November 2015 in “Pharmacopsychiatry” This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.
14 citations
,
December 2016 in “Sexual Medicine” This study identified differences in adverse symptoms among patients with post-finasteride syndrome based on short and long androgen receptor gene polymorphisms.
14 citations
,
April 2014 in “Medical Clinics of North America” This review discusses common skin conditions in primary care settings and provides guidance on differential diagnoses and selecting appropriate topical treatments, but it reports no new clinical results.
14 citations
,
August 2013 in “Facial Plastic Surgery Clinics of North America” This review discusses current and emerging medical therapies for androgenetic alopecia but reports no new clinical findings, emphasizing the importance of stabilizing the condition as a complement to surgical hair restoration.
13 citations
,
November 2012 in “PubMed” This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.
12 citations
,
June 2016 in “Reviews in Endocrine and Metabolic Disorders” This review discusses various genetic and acquired skin diseases that can affect male fertility, highlighting the clinical management challenges and reports no new research findings.
11 citations
,
August 2014 in “Current Urology Reports” This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.
10 citations
,
February 2020 in “Endocrine” This study found that finasteride treatment in males with androgenetic alopecia was linked to significant changes in sperm parameters and increased testosterone levels, but no sexual dysfunction was observed, and sperm parameters returned to baseline after treatment stopped.
9 citations
,
November 2019 in “Scientific reports” This study isolated a bioactive peptide from Trapa japonica fruit and found that it may protect human dermal papilla cells from DHT-induced stress, suggesting potential for biomedical applications.
6 citations
,
December 2020 in “Dermatological reviews” This review discusses the potential link between androgenic alopecia, androgens, and the severity of COVID-19, highlighting possible therapeutic targets but reports no new clinical results.
4 citations
,
July 2021 in “Journal of Dermatological Treatment” This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.
3 citations
,
May 2013 in “Journal of the American Association of Nurse Practitioners” This review evaluates six primary studies on androgenetic alopecia treatments and suggests topical minoxidil or finasteride as first-line options, recommending further research into treatments and practice guidelines.
1 citations
,
January 2005 in “Side effects of drugs annual” This chapter reviews various dermatological drugs and treatments, highlighting adverse effects, with no new clinical findings reported.
October 2025 in “Clinical Cosmetic and Investigational Dermatology” This study established consensus guidelines for diagnosing and managing androgenetic alopecia in Egypt, emphasizing individualized care and emerging therapies based on a survey of Egyptian dermatologists and refinement through expert review.
October 2023 in “International journal of biology, pharmacy and allied sciences” This article provides an in-depth exploration of both natural and synthetic treatments for alopecia, examining their mechanisms, benefits, limitations, and current research, while noting that synthetic therapies can have potential adverse effects.
November 2020 in “Elsevier eBooks” This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
Different drugs are used to manage breeding, prevent or end pregnancy, and treat reproductive issues in dogs and cats.
September 2012 in “African Journal of Urology” This review describes the clinical features of testosterone deficiency syndrome in aging men but reports no new experimental findings, highlighting the need for clinical recognition and treatment of TDS.
This chapter reviews the causes, prevalence, and prognosis of androgenetic alopecia and discusses treatments like topical minoxidil and systemic finasteride to stop hair loss and potentially increase hair density.
April 2008 in “Blackwell Publishing Ltd eBooks” AGA causes permanent hair loss; minoxidil helps men, finasteride helps men, minoxidil somewhat helps women, estrogens/antiandrogens lack evidence for women.
35 citations
,
April 2013 in “Sexual medicine reviews” This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.
72 citations
,
April 2008 in “The Journal of urology/The journal of urology” This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.
67 citations
,
February 2015 in “Life Sciences” This review discusses phytotherapy options for managing benign prostatic hyperplasia, noting some herbal agents show promise in trials for mild-moderate symptoms but more evidence is needed for others.
31 citations
,
January 2014 in “Journal of endocrinological investigation” This study reviewed Woodhouse-Sakati syndrome and found it consistently associated with hypogonadism, decreased IGF1, and frontotemporal alopecia, with additional symptoms like intellectual disabilities and diabetes in some patients.
29 citations
,
December 1998 in “Seminars in Cutaneous Medicine and Surgery” This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.
14 citations
,
April 2006 in “Expert Review of Dermatology” This review discusses therapeutic options for androgenetic alopecia, noting that while antiandrogen treatments prevent further hair loss and promote some regrowth, dramatic results are rare.